Scarica l'app Stockscreener
44.25
0.32%
0.14
Dopo l'orario di chiusura:
44.30
0.05
+0.11%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché SNY Giù?
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$44.11
Aprire:
$44.11
Volume 24 ore:
1.63M
Relative Volume:
0.57
Capitalizzazione di mercato:
$105.92B
Reddito:
$49.41B
Utile/perdita netta:
$5.59B
Rapporto P/E:
18.53
EPS:
2.3875
Flusso di cassa netto:
$8.32B
1 W Prestazione:
-1.71%
1M Prestazione:
+3.24%
6M Prestazione:
-9.10%
1 anno Prestazione:
-12.95%
Intervallo 1D:
$44.02
$44.51
Intervallo di 1 settimana:
$43.35
$44.85
Portata 52W:
$42.28
$52.68
Sanofi Adr Stock (SNY) Company Profile
Nome
Sanofi Adr
Settore
Industria
Telefono
-
Indirizzo
-
Compare SNY vs LLY, JNJ, ABBV, MRK, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SNY
Sanofi Adr
|
44.25 | 105.92B | 49.41B | 5.59B | 8.32B | 2.3875 |
LLY
Lilly Eli Co
|
1,133.00 | 1.01T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
240.87 | 579.83B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
227.73 | 402.35B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
119.05 | 294.03B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
153.07 | 292.07B | 54.66B | 13.58B | 16.05B | 7.0171 |
Sanofi Adr Stock (SNY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-20 | Downgrade | BNP Paribas Exane | Outperform → Neutral |
| 2026-02-12 | Downgrade | BofA Securities | Buy → Neutral |
| 2026-01-27 | Iniziato | Citigroup | Neutral |
| 2026-01-16 | Downgrade | UBS | Buy → Neutral |
| 2026-01-06 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-12-09 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-12-08 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-09-08 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-09-02 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2025-08-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-04-15 | Iniziato | Exane BNP Paribas | Outperform |
| 2025-03-21 | Iniziato | Goldman | Neutral |
| 2025-01-30 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-07-26 | Reiterato | Argus | Buy |
| 2024-01-23 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-01-16 | Ripresa | UBS | Buy |
| 2023-12-05 | Downgrade | JP Morgan | Overweight → Neutral |
| 2023-10-30 | Downgrade | Stifel | Buy → Hold |
| 2023-09-06 | Aggiornamento | Berenberg | Hold → Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-04-28 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-03-27 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2022-12-13 | Ripresa | Morgan Stanley | Overweight |
| 2022-08-12 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-08-09 | Downgrade | UBS | Buy → Neutral |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2021-09-27 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-01-15 | Iniziato | Deutsche Bank | Sell |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-03-17 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2020-03-11 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-02-11 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-01-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-09-20 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-09-03 | Iniziato | Bernstein | Outperform |
| 2019-08-14 | Aggiornamento | UBS | Neutral → Buy |
| 2018-12-11 | Aggiornamento | Jefferies | Hold → Buy |
| 2018-11-01 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2018-10-09 | Iniziato | Guggenheim | Neutral |
| 2018-09-10 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2018-08-10 | Aggiornamento | Citigroup | Neutral → Buy |
| 2018-03-23 | Aggiornamento | Liberum | Hold → Buy |
| 2018-01-23 | Downgrade | Barclays | Equal Weight → Underweight |
| 2017-12-06 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2017-12-01 | Downgrade | Morgan Stanley | Overweight → Underweight |
| 2017-11-15 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2017-08-30 | Aggiornamento | HSBC Securities | Reduce → Hold |
Mostra tutto
Sanofi Adr Borsa (SNY) Ultime notizie
Sanofi S.A. Stock (FR0000120578): FDA accelerated approval for Tzield puts diabetes franchise in foc - AD HOC NEWS
Communiqué de presse : Le Tzield de Sanofi approuvé aux États-Unis comme première thérapie modificatrice de la maladie pour les patients récemment diagnostiqués avec un diabète de type 1 au stade 3 - GlobeNewswire Inc.
Sanofi S.A. Stock (FR0000120578): Valuation Metrics Under the Microscope - AD HOC NEWS
Sanofi S.A. Stock (FR0000127771): Stock in focus as no fresh trigger is verified - AD HOC NEWS
Sanofi S.A. stock (FR0000127771): Diabetes focus and pipeline news keep Big Pharma in motion - AD HOC NEWS
European ADRs Started The Week In The Green - Finimize
Sanofi S.A. stock (FR0000127771): diabetes deal and pipeline focus move into the spotlight - AD HOC NEWS
Sanofi-Owkin Expand AI Collaboration With New Agentic AI Initiative - Sahm
Senior Chinese legislator meets Myanmar's foreign minister - news.cgtn.com
Sanofi (SASY) Stock: Pharma Giant Launches AI Sales Agent Built on Snowflake - MEXC
SNY Stock Price, Quote & Chart | SANOFI-ADR (NASDAQ:SNY) - ChartMill
Sanofi S.A. stock (FR0000120578): analyst consensus steady as ADRs trade in low-40s USD range - AD HOC NEWS
Sanofi S.A. stock (FR0000127771): Analyst consensus points to hold stance as shares hover in low-40s - AD HOC NEWS
Sanofi S.A. stock (FR0000127771): Technical picture and price action on Euronext Paris - AD HOC NEWS
Sanofi S.A. stock (FR0000120578): Vaccine and obesity focus after Q1 2026 earnings - AD HOC NEWS
Sanofi S.A. stock (FR0000120578): Q1 results, pipeline focus and outlook for US investors - AD HOC NEWS
SANOFI-ADR (NASDAQ:SNY): A Quality Dividend Stock with a 5.31% Yield and Strong Fundamentals - ChartMill
Publicis Groupe stock (FR0000120578): LiveRamp deal and AI push keep investors focused - AD HOC NEWS
Publicis Groupe S.A. stock (FR0000120578): LiveRamp deal and AI push reshape data strategy - AD HOC NEWS
Sanofi S.A. stock (FR0000127771): EU green light for multiple myeloma drug Sarclisa draws investor f - AD HOC NEWS
Sanofi S.A. stock (FR0000127771): Vaccine unit and new drug launches keep investors alert - AD HOC NEWS
Sanofi S.A. stock (FR0000120578): Q1 beat and pipeline focus keep investors watching - AD HOC NEWS
Sanofi stock (FR0000120578): Pipeline updates keep investors watching - AD HOC NEWS
Sanofi stock (FR0000120578): trial data and EU approval updates - AD HOC NEWS
Sanofi stock (FR0000120578): Dupixent data and AI investment keep focus on growth - AD HOC NEWS
Sanofi stock (FR0000120578): FDA, dividend and Dupixent keep investors focused - AD HOC NEWS
Sanofi S.A. stock (FR0000127771): Q1 figures, GLP-1 hopes and focus on pipeline value - AD HOC NEWS
Sanofi S.A. stock (FR0000120578): Q1 2026 results reviewed - AD HOC NEWS
Sanofi S.A. stock (FR0000120578): Global pharma leader's business and market position - AD HOC NEWS
Sanofi S.A. stock (FR0000127771): Recent earnings and pipeline updates - AD HOC NEWS
Sanofi (NASDAQ:SNY) Emerges as a Decent Value Pick with Strong Fundamentals - ChartMill
Sanofi Supports AlphaDetect to Accelerate Detection of Alpha-1 - ChartMill
European ADRs Open The Week Lower In US Trading - Finimize
Communiqué de presse : Assemblée Générale Annuelle du 29 avril 2026 - GlobeNewswire Inc.
FDA Approval Broadens Dupixent Use While Sanofi Posts Earnings Beat - Sahm
Sanofi Eyes First On-Body Injector Cancer Therapy As FDA Delays Decision - Sahm
Earnings call transcript: Sanofi’s Q1 2026 earnings beat forecasts, stock rises - Investing.com
Earnings call transcript: Sanofi’s Q1 2026 earnings beat forecasts, stock rises By Investing.com - Investing.com Canada
Sanofi Adr Azioni (SNY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.15%
0.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):